Core Viewpoint - The stock of Zai Lab Limited (药捷安康-B) surged over 25% following the announcement of new research data on its core product, Tiengogatinib, for cholangiocarcinoma at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] Company Summary - Zai Lab's Tiengogatinib is an innovative multi-target small molecule kinase inhibitor developed in-house, currently in the registration clinical phase [1] - The drug targets tumor cells and improves the tumor microenvironment to exert anti-tumor effects [1] - Tiengogatinib is undergoing multiple clinical trials for cholangiocarcinoma, prostate cancer, and breast cancer in both the US and China [1] Regulatory Approvals - Tiengogatinib has received several designations, including Orphan Drug Designation (ODD) and Fast Track Designation from the US FDA for cholangiocarcinoma and prostate cancer [1] - The drug is also included in the breakthrough therapy list approved by China's NMPA and has received ODD from the European EMA for cholangiocarcinoma [1]
港股异动 | 药捷安康-B(02617)一度涨超25% 于2025年ESMO年会上公布替恩戈替尼研究数据并获口头报告